CYSTIC Fibrosis Victoria chief executive officer Helen McNeill remains hopeful Kalydeco will be approved by the Pharmaceutical Benefits Advisory Committee in November.
The PBAC deferred a decision to approve the drug for Cystic Fibrosis genetic mutation on G551D in August.
Ms McNeill said it was most likely because the committee required more information.
"We don’t know what's happening behind the scenes but we are very hopeful there will be a decision made in November," she said.
Ms McNeill said there had been several examples of other drugs being considered three or four times by the PBAC before approval.
Ms McNeill said the cystic fibrosis community would continue to fight for the drug.
"We certainly won’t be giving up.
"It is important for the CF community that this is approved. It can change lives."